Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
LONDON, May 26, 2026 /PRNewswire/ — Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”) today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”) and related post-acute infection syndromes (“PAIS”). In the pilot dataset, ViraxImmune™ demonstrated measurable separation between PAIS patients and healthy controls, achieving 88% specificity and 92% positive predictive value (“PPV”) — early performance metrics that Virax believes support continued development and advancement into larger clinical validation… Read the full Press Release here
Virax Biolabs’ Q2 2026 Investor Presentation: Next-Generation Diagnostics for Chronic Inflammation and Immune Dysfunction
The Virax Biolabs updated investor presentation for Q2 2026 has just been released. This deck provides an overview of our current clinical milestones and strategic roadmap for the coming months. You can review the full presentation below or download a copy for your records: Q2 2026 Investor Presentation
Virax Biolabs’ CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
Virax Biolabs’ proprietary in-development diagnostic technology for post-acute infection syndromes (“PAIS”), such as Long COVID, positions the Company for an important data year ahead, following a series of recent clinical and operational milestones over the past 12 months. LONDON, Dec. 3, 2025 /PRNewswire/ — Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, today highlighted key milestones, achievements and clinical progress while outlining its strategic priorities for 2026 in a letter to shareholders and investors. Read the full Press Release here
Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September
Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy
Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
Read Our Press Release
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
Virax Biolabs Presentation from the 19th World Immune Regulation Meeting: “Evaluation of T cell dysfunction in Post Acute Infection Syndromes”
Dr. Nigel McCracken, our Chief Operating Officer, will present on “Evaluation of T cell dysfunction in Post Acute Infection Syndromes” at the 19th World Immune Regulation Meeting (WIRM) in Davos, Switzerland today (March 12th) at 8pm in Foyer A1. For those not able to join us in Davos, you can have a look at the poster here or use the link below to download a copy for a closer look:
Virax Biolabs to Present at 19th World Immune Regulation Meeting
Virax Biolabs Presents at H.C. Wainwright’s 26th Annual Global Investment Conference
